CAMP4 Therapeutics Corporation (CAMP)

In the past six months, CAMP4 Therapeutics reported its Q4 and full-year 2025 financial results, with an EPS of -$0.87 and revenue of $0.35 million, ending 2025 with $109.5 million in cash. The company entered a strategic research and licensing agreement with GSK, receiving a $17.5 million upfront payment. It completed a private placement providing $50 million upfront and a $30 million underwritten equity offering. Michael MacLean was appointed to the Board of Directors. CAMP4 participated in investor conferences, including the 44th Annual J.P. Morgan Healthcare Conference. The company announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock has seen significant volatility, with a reported increase of 181.8% but also a 29.69% decline year-to-date as of March 27, 2026, and a substantial decline of 73.76% in Q2 2025.

As a clinical-stage biopharmaceutical company with products in development, CAMP4 Therapeutics does not exhibit discernible demand seasonality. Its revenue is primarily from collaboration agreements rather than product sales.

CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics for genetic diseases. The company's core business involves discovering and developing regulatory RNA therapeutics to upregulate gene expression and restore healthy protein levels, utilizing its proprietary RNA Actuating Platform. Its pipeline is focused on metabolic and central nervous system disorders. CMP-CPS-001 is in Phase 1/2 clinical trial for urea cycle disorders, aiming to improve urea cycle activity by amplifying CPS1 expression, but further investment is paused while exploring partnership opportunities. CMP-SYNGAP focuses on SYNGAP1-related disorders, with CMP-SYNGAP-01 undergoing toxicology studies for a planned Phase 1/2 clinical trial in the second half of 2026.

CAMP4 Therapeutics Corp. is headquartered in Cambridge, Massachusetts, United States.

CAMP4 Therapeutics' reputation is tied to its scientific progress, clinical trial outcomes, and financial stability. The company has a consensus rating of "Hold" from analysts, with an average rating score of 2.40. The stock price decline in Q2 2025 and year-to-date decrease as of March 27, 2026, could negatively impact investor confidence, while positive news like the GSK collaboration and financing rounds can bolster confidence. Board appointments and participation in investor conferences are viewed positively.

CAMP4 Therapeutics Corp. has a mixed ownership structure. Institutional investors hold approximately 41.76% to 49.30% of the company's stock, with major holders including Janus Henderson Group PLC, Vivo Capital LLC, and Balyasny Asset Management L.P. Insiders collectively own about 28.09% to 33.60% of the company's stock, including individuals like Amir Nashat, Josh Mandel-Brehm, and Richard A. Young. The general public holds around 12% to 22.61% of the company.